Severe cardiac toxicity after monoclonal antibody therapy [3]

European Journal of Haematology

Volumn 68, Issue 5, 2002, Pages 324-

  Damaj, G ^a,b   Rubio, M T ^a   Audard, V ^a   Hermine, O ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; MONOCLONAL ANTIBODY; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ADULT; CARDIOTOXICITY; CASE REPORT; CHILL; DIARRHEA; DYSPNEA; FEVER; HUMAN; HYPOTENSION; LETTER; MALE; NAUSEA; PRIORITY JOURNAL; RASH; RIGOR; T CELL LYMPHOMA; TREATMENT FAILURE; URTICARIA;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION;

EID: 0036345646     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.00712.x     Document Type: Letter

References (4)

1. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
2. A UK multicentre phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response
3. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation
4. Coronary artery spasm does not depend on the intracellular calcium store but is substantially mediated by the protein kinase C-mediated pathway in a swine model with interleukin-1 beta in vivo